Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin and Social Cognition in Schizophrenia (fMRI)
NCT02566356Phase 1Completed
- Sponsor
- University of California, San Francisco
- Start
- Sep 2012
- Primary completion
- Sep 2017
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of oxytocin nasal spray in schizophrenia, sponsored by University of California, San Francisco. Primary endpoint: Change in fMRI neural activation patterns at 2 days. Started Sep 2012; status: completed.
02
Drugs
oxytocin nasal spray
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02566356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02566356.